Similarly, the KM DSS analysis revealed that EPHX2 acted as a protective factor for patients with ACC, KIRC, KIRP, MESO, PAAD, and UVM, and as a risk factor for patients with LGG (Figure 3B). This evidence concerns the gene EPHX2 and adrenal cortex carcinoma.